Industry News/Transfusion

Company Plans Phase III Trial of Blood Platelet Drug

Published in Blood Weekly, May 29th, 1995

Genetics Institute Inc., Cambridge, Massachusetts, announced positive results of a Phase II study of recombinant human interleukin-eleven (rhIL-11).

In the study, rhIL-11 restored platelets in thrombocytopenic (platelet-depleted) patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions when compared to patients on placebo.

Based on this favorable outcome, Genetics Institute also announced that it plans to begin a Phase III study of rhIL-11 by the end of 1995. In addition, the company expects to have results from two additional Phase II studies later in 1995.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry